Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay.
D000073:Acenaphthenes; D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005069:Evaluation Studies as Topic; D006248:Harringtonines / Q000627:therapeutic use* / Q000633:toxicity; D000077863:Homoharringtonine; D006801:Humans; D007668:Kidney; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D012265:Ribonucleotides / Q000627:therapeutic use* / Q000633:toxicity
D000073:Acenaphthenes; D000470:Alkaloids; D006248:Harringtonines; D012265:Ribonucleotides; C014205:triciribine phosphate; D000077863:Homoharringtonine